Sofinnova Investments’s Protagonist Therapeutics PTGX Stock Holding History

Sofinnova Investments’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-547,441	Closed	-$6.62M	–	68
2022 Q1	$13M	Buy	547,441 +65,184	+14%	+$1.84M	0.98%	26
2021 Q4	$16.5M	Buy	482,257 +184,548	+62%	+$5.83M	0.96%	27
2021 Q3	$5.28M	Sell	297,709 -151,373	-34%	-$6.45M	0.31%	55
2021 Q2	$20.2M	Sell	449,082 -205,818	-31%	-$6.79M	1.16%	23
2021 Q1	$17M	Buy	+654,900	New	+$16.6M	1.02%	27
2020 Q4	–	Sell	-357,769	Closed	-$6.99M	–	78
2020 Q3	$6.99M	Buy	357,769 +31,705	+10%	+$595K	0.52%	33
2020 Q2	$5.76M	Buy	+326,064	New	+$4.09M	0.36%	51

Other funds holding PTGX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sofinnova Investments's PTGX Position: Q2 2022 in Review

Sofinnova Investments sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 547,441 shares — an estimated $6.62M sold.

Sofinnova Investments first reported a position in PTGX in Q2 2020 and held it in 7 quarters. The position peaked at $20.2M in Q2 2021. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

Sofinnova Investments reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
Sofinnova Investments sold 547,441 Protagonist Therapeutics shares in Q2 2022, an estimated $6.62M.
Sofinnova Investments first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 7 quarters.
Sofinnova Investments's Protagonist Therapeutics position peaked at $20.2M in Q2 2021.
130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on Sofinnova Investments's 13F filing for Q2 2022, filed 15 Aug 2022.